MedTrace Logo

The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors

NCT04469582 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2020-09-23

No results posted yet for this study

Summary

The investigators conducted a prospective study which included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019. 113 consecutive patients with BP were identified. The investigators included the patients with type 2 diabetes and investigated the percentage of patients who were under treatment with DPP4-is. The specific DPP4-i prescribed was also documented.Medical information including patients' age, sex, other comorbidities and concomitant medications were also recorded. Furthermore, the investigators evaluated the effect of different types of treatment (topical steroids, systemic corticosteroids, immunosuppressive agents) on bullous pemphigoid.

Conditions

  • Bullous Pemphigoid

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Vaia Lambadiari, MD,PhD · 2nd department of internal medicine,University of Athens,Greece

  • Evangelia Papadavid, MD,PhD · 2nd department of dermatology and venereology,University of Athens, Greece

  • Aikaterini Kountouri, MD · 2nd department of internal medicine,University of Athens,Greece

  • Emmanouil Korakas, MD · 2nd department of internal medicine,University of Athens,Greece

  • Sofia Theotokoglou · 2nd department of dermatology and venereology,University of Athens, Greece

  • Konstantinos Theodoropoulos · 2nd department of dermatology and venereology,University of Athens, Greece

  • Ignatios Ikonomidis, MD,PhD · 2nd department of cardiology,University of Athens,Greece

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-01
Primary Completion
2020-09-09
Completion
2020-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469582 on ClinicalTrials.gov